Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AstraZeneca
Study shows proton pump inhibitor Nexium helps patients with Zollinger-Ellison syndrome
June 23rd, 2006
A new clinical study shows that the proton pump inhibitor (PPI) Nexium (esomeprazole magnesium) maintained normal gastric (stomach) acid levels in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion (IGH). Results of the 12-month, multicenter study were presented at the annual Digestive Disease Week (DDW). Nexium is indicated for the treatment of GERD and for NSAID-associated gastric ulcers in as-risk patients and is under investigation for Zollinger-Ellison syndrome. Zollinger-Ellison syndrome (ZES), a rare but serious chronic condition, is characterized by the development of a tumor or tumors that secrete excessive...
Source: Biotech Law Weekly (2006-06-23)
|
